Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970201 | 0.95 | GPR119 (0.49) | TP53GPR119CYP3A4CYP2C9 | |
| SCHEMBL14966130 | 0.89 | GPR119 (0.54) | TP53GPR119CYP3A4CYP2C9 | |
| SCHEMBL16169603 | 0.88 | TP53 (0.59) | TP53GPR119 | |
| SCHEMBL14978691 | 0.86 | TP53 (0.37) | TP53GPR119 | |
| SCHEMBL14966666 | 0.85 | GPR119 (0.49) | TP53GPR119 | |
| SCHEMBL14968960 | 0.85 | GPR119 (0.52) | TP53GPR119CYP3A4CYP2C9 | |
| SCHEMBL14970194 | 0.81 | GPR119 (0.48) | TP53GPR119 | |
| SCHEMBL14969462 | 0.81 | GPR119 (0.54) | TP53GPR119CYP3A4 | |
| SCHEMBL14978753 | 0.81 | TP53 (0.42) | TP53GPR119 | |
| Trifluoroacetic Acid SCHEMBL16163152 | 0.80 | TP53 (0.37) | TP53GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | TP53 4454/4885GPR119 1/4885CYP3A4 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.